Drug intelligence / Profile preview

CT3000

Development stage: Preclinical
Lead developer: Pelthos Therapeutics
Modality: Small Molecules

Overview

CT3000 is a drug candidate developed as part of a NaV1.7 pain program, initially by Channel Therapeutics and subsequently by Pelthos Therapeutics following a business combination. It is designed as a non-opioid therapeutic for pain management, functioning as a NaV1.7 blocker. The asset was part of the pipeline acquired by Pelthos Therapeutics, which aims to advance its clinical programs for non-opioid pain therapeutics.

Targets

SCN9A (Sodium channel protein type 9 subunit alpha)

Beyond the preview

Go deeper on CT3000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT3000.

Explore the full profile